

CLAIMS

1. A pharmaceutical composition for the treatment of wounds, comprising: a therapeutically effective amount of a polypeptide of SEQ ID NO. 1 or 2, or a derivative or analog thereof, and pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is in the form of a solution, a cream, an ointment, a paste, a lotion, an ointment, a foam, a spray, a transdermal patch, or a gel.
3. The pharmaceutical composition of claim 1 or 2, wherein the therapeutically effective amount of the polypeptide of SEQ ID NO. 1 or 2, or a derivative or analog thereof, ranges from about 0.1 µg/mL to about 10 µg/mL.
4. The pharmaceutical composition of claim 3, wherein the therapeutically effective amount of the polypeptide of SEQ ID NO. 1 or 2, or a derivative or analog thereof is about 2 µg/mL.
5. The pharmaceutical composition of any one of claims 1 to 4, wherein the pharmaceutical carrier is selected from a modified cellulose, hypromellose, physiological buffer, gelatin, hydrogel, oil, alcohol, petrolatum, propylene glycol, and glycerin, or a combination thereof.
6. The pharmaceutical composition of claim 5, wherein the pharmaceutical carrier is a modified cellulose selected from hydroxypropyl cellulose (HPMC), carboxymethylcellulose (CMC), and hydroxyethylmethyl cellulose (HEMC).
7. The pharmaceutical composition of claim 6, wherein the pharmaceutical carrier is HPMC.
8. The pharmaceutical composition of claim 7, wherein the HPMC is present in an amount of from about 0.5% w/w to about 10% w/w.

9. Use of a pharmaceutical composition of any one of claims 1 to 8 in the manufacture of a medicament for the treatment of a wound in a mammal.

10. Use of a pharmaceutical composition of any one of claims 1 to 8 in the manufacture of a medicament for promoting wound healing in a mammal.

11. The use of claim 9 or 10, wherein the wound comprises a skin ulcer, an infectious wound, an ischemic wound, a surgical wound, or a skin wound from radiation poisoning, or a combination thereof.

12. The use of claim 11, wherein the wound is a skin ulcer comprising a neuropathic ulcer an ischemic ulcer, or a neuroischemic ulcer, or a combination thereof.

13. The use of any one of claims 9 to 12, wherein the medicament, in use, increases collagen production when compared to an untreated control.

14. The use of any one of claims 9 to 13, wherein the medicament, in use, increases elastin production when compared to an untreated control.

15. The use of any one of claims 9 to 14, wherein the medicament is formulated for application to the wound with a therapeutically effective amount of a human platelet-derived growth factor-BB (rh-PDGF-BB), a human Transforming Growth Factor-alpha (rh-TGF-alpha), or a combination thereof.

16. A pharmaceutical composition for topical administration comprising a peptide having at least 90% sequence identity to SEQ ID NO. 1 or 2, or a derivative or analog thereof, and a pharmaceutical vehicle.

17. A peptide having at least 90% sequence identity to SEQ ID NO. 1 or 2, or a derivative or analog thereof, for topical use in promotion of wound healing.

18. Use of a composition comprising a peptide according to SEQ ID NO. 1 or 2, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of wounds.